Henry Schein, Inc. HSIC
86.37
0.84
0.98%
as of 25 Sep
- Market cap
- $9.5B
- P/E
- 25.0×
Follow HSIC
Indexes
indicate stock being part of an index,
Insider Buys
alert about insiders buying in the last 12 month
Henry Schein, Inc. (HSIC) P/E ratio
As of 25 September 2026, Henry Schein, Inc. (HSIC) trades at a P/E ratio of 25.0×. Over the past ten years it has ranged from 9.1× (March 2020) to 31.7× (November 2024); the current reading is higher than 91% of that period. That is above the Healthcare sector median of 22.7×.
P/E ratio, daily
Annual
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 22.9× | 1.61% |
| FY2024 | 22.5× | (5.14%) |
| FY2023 | 23.8× | 17.31% |
| FY2022 | 20.3× | 17.56% |
| FY2021 | 17.2× | (27.07%) |
| FY2020 | 23.6× | 67.49% |
| FY2019 | 14.1× | (19.37%) |
| FY2018 | 17.5× | (19.79%) |
| FY2017 | 21.8× | 11.63% |
| FY2016 | 19.5× | (8.99%) |
Quarterly
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 24.1× | 9.39% |
| Mar 2026 | 22.1× | (3.65%) |
| Dec 2025 | 22.9× | 10.08% |
| Sep 2025 | 20.8× | (10.57%) |
| 42 more quarters | Free account |
Against its own ten years
Low 9.1×
High 31.7×
Ten-year median
20.8×
Current reading's percentile
91
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| COSM Cosmos Health Inc. compare | n/m |
| ACH Accendra Health, Inc. compare | n/m |
| FOCL FocalTherics compare | n/m |
| AHG Akso Health Group Sponsored ADR compare | n/m |
| YI 111, Inc. Sponsored ADR compare | n/m |
| COR Cencora, Inc. compare | 22.7× |
| MCK McKesson Corporation compare | 23.1× |
| HSIC Henry Schein, Inc. | 25.0× |
| CAH Cardinal Health, Inc. compare | 30.3× |
| Healthcare sector median | 22.7× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on HSIC
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement